{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T21:12:39Z","timestamp":1788556359259,"version":"build-2803163510"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["heartandlung.org","clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart & Lung"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.hrtlng.2024.07.010","type":"journal-article","created":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:18:38Z","timestamp":1722471518000},"page":"242-253","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["A systematic review and meta-analysis of the clinical benefits and adverse reactions of anti-fibrotics in non-IPF progressive fibrosing ILD"],"prefix":"10.1016","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2070-3585","authenticated-orcid":false,"given":"Woon Hean","family":"Chong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipika","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze Ying","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sridhar","family":"Venkateswaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeline Yit Ying","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching Yee","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norris Chun Ang","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noel Stanley Wey Tut","family":"Tay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.hrtlng.2024.07.010_bib0001","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","article-title":"Diagnosis of idiopathic pulmonary fibrosis. an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"198","author":"Raghu","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.hrtlng.2024.07.010_bib0002","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01209-2017","article-title":"Idiopathic pulmonary fibrosis: lessons from clinical trials over the past 25\u2005years","volume":"50","author":"Raghu","year":"2017","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.hrtlng.2024.07.010_bib0003","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","article-title":"An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management","volume":"183","author":"Raghu","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.hrtlng.2024.07.010_bib0004","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1165\/rcmb.2019-0328TR","article-title":"Pirfenidone: molecular mechanisms and potential clinical applications in lung disease","volume":"62","author":"Ruwanpura","year":"2020","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"5","key":"10.1016\/j.hrtlng.2024.07.010_bib0005","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1183\/09031936.00174914","article-title":"Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis","volume":"45","author":"Wollin","year":"2015","journal-title":"Eur Respir J"},{"issue":"22","key":"10.1016\/j.hrtlng.2024.07.010_bib0006","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N Engl J Med"},{"issue":"9779","key":"10.1016\/j.hrtlng.2024.07.010_bib0007","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","article-title":"Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials","volume":"377","author":"Noble","year":"2011","journal-title":"The Lancet"},{"issue":"22","key":"10.1016\/j.hrtlng.2024.07.010_bib0008","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.hrtlng.2024.07.010_bib0009","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1103690","article-title":"Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis","volume":"365","author":"Richeldi","year":"2011","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.hrtlng.2024.07.010_bib0010","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1164\/rccm.201506-1063ST","article-title":"An official ATS\/ERS\/JRS\/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. an update of the 2011 Clinical Practice Guideline","volume":"192","author":"Raghu","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.hrtlng.2024.07.010_bib0011","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00296-020-04565-w","article-title":"Efficacy and safety of pirfenidone in systemic sclerosis-related interstitial lung disease-a randomised controlled trial","volume":"40","author":"Acharya","year":"2020","journal-title":"Rheumatol Int"},{"issue":"5","key":"10.1016\/j.hrtlng.2024.07.010_bib0012","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S2213-2600(20)30554-3","article-title":"Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial","volume":"9","author":"Behr","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.hrtlng.2024.07.010_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.897102","article-title":"Efficacy of pirfenidone vs. placebo in unclassifiable interstitial lung disease, by surgical lung biopsy status: data from a post-hoc analysis","volume":"9","author":"Molina-Molina","year":"2022","journal-title":"Front Med"},{"issue":"2","key":"10.1016\/j.hrtlng.2024.07.010_bib0014","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S2213-2600(19)30341-8","article-title":"Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"8","author":"Maher","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.hrtlng.2024.07.010_bib0015","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S2213-2600(22)00260-0","article-title":"Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study","volume":"11","author":"Solomon","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.hrtlng.2024.07.010_bib0016","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S2213-2600(20)30036-9","article-title":"Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial","volume":"8","author":"Wells","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"26","key":"10.1016\/j.hrtlng.2024.07.010_bib0017","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis\u2013associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.hrtlng.2024.07.010_bib0018","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.hrtlng.2024.07.010_bib0019","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1136\/thorax-2022-219795","article-title":"Pirfenidone in fibrotic hypersensitivity pneumonitis: a double-blind, randomised clinical trial of efficacy and safety","volume":"78","author":"Fern\u00e1ndez P\u00e9rez","year":"2023","journal-title":"Thorax"},{"key":"10.1016\/j.hrtlng.2024.07.010_bib0020","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.hrtlng.2024.07.010_bib0021","series-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.2. 2021;Cochrane","author":"Higgins","year":"2021"},{"issue":"3","key":"10.1016\/j.hrtlng.2024.07.010_bib0022","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"issue":"7414","key":"10.1016\/j.hrtlng.2024.07.010_bib0023","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"12","key":"10.1016\/j.hrtlng.2024.07.010_bib0024","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.rmed.2011.08.015","article-title":"Does the presence of connective tissue disease modify survival in patients with pulmonary fibrosis?","volume":"105","author":"Navaratnam","year":"2011","journal-title":"Respir Med"},{"issue":"1","key":"10.1016\/j.hrtlng.2024.07.010_bib0025","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12931-014-0154-6","article-title":"Predictors of diagnosis and survival in idiopathic pulmonary fibrosis and connective tissue disease-related usual interstitial pneumonia","volume":"15","author":"Moua","year":"2014","journal-title":"Respir Res"},{"key":"10.1016\/j.hrtlng.2024.07.010_bib0026","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.rmed.2016.02.003","article-title":"Lung function decline over 25 years of follow-up among black and white adults in the ARIC study cohort","volume":"113","author":"Mirabelli","year":"2016","journal-title":"Respir Med"},{"key":"10.1016\/j.hrtlng.2024.07.010_bib0027","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.778649","article-title":"Autoimmune progressive fibrosing interstitial lung disease: predictors of fast decline","volume":"12","author":"Nagy","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.hrtlng.2024.07.010_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2021.106574","article-title":"Efficacy and safety of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: subgroup analysis of the randomised, double-blind, placebo-controlled, phase 3 INBUILD trial","volume":"187","author":"Inoue","year":"2021","journal-title":"Respir Med"},{"issue":"2","key":"10.1016\/j.hrtlng.2024.07.010_bib0029","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.resinv.2020.10.005","article-title":"Efficacy and safety of nintedanib in Asian patients with systemic sclerosis-associated interstitial lung disease: subgroup analysis of the SENSCIS trial","volume":"59","author":"Azuma","year":"2021","journal-title":"Respir Investig"},{"issue":"1","key":"10.1016\/j.hrtlng.2024.07.010_bib0030","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/14397595.2020.1751402","article-title":"Nintedanib in patients with systemic sclerosis-associated interstitial lung disease: a Japanese population analysis of the SENSCIS trial","volume":"31","author":"Kuwana","year":"2021","journal-title":"Mod Rheumatol"},{"issue":"6","key":"10.1016\/j.hrtlng.2024.07.010_bib0031","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1513\/AnnalsATS.202103-342OC","article-title":"Pirfenidone in progressive pulmonary fibrosis: a systematic review and meta-analysis","volume":"19","author":"Ghazipura","year":"2022","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.hrtlng.2024.07.010_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2023.107329","article-title":"Efficacy and safety of antifibrotic agents in the treatment of CTD-ILD and RA-ILD: a systematic review and meta-analysis","volume":"216","author":"Yang","year":"2023","journal-title":"Respir Med"},{"issue":"5","key":"10.1016\/j.hrtlng.2024.07.010_bib0033","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1183\/09031936.00131813","article-title":"6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis","volume":"43","author":"du Bois","year":"2014","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.hrtlng.2024.07.010_bib0034","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s12890-019-0943-2","article-title":"Demographic and clinical predictors of progression and mortality in connective tissue disease-associated interstitial lung disease: a retrospective cohort study","volume":"19","author":"Chan","year":"2019","journal-title":"BMC Pulm Med"},{"issue":"7","key":"10.1016\/j.hrtlng.2024.07.010_bib0035","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1164\/rccm.200607-912OC","article-title":"Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes","volume":"175","author":"Park","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"22","key":"10.1016\/j.hrtlng.2024.07.010_bib0036","first-page":"00098","article-title":"Chronic dyspnea with Raynaud's phenomenon and elevated ANA: a diagnosis of systemic sclerosis sine scleroderma","volume":"S0002-9629","author":"Chong","year":"2022","journal-title":"Am J Med Sci"},{"issue":"4","key":"10.1016\/j.hrtlng.2024.07.010_bib0037","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.amjms.2020.11.012","article-title":"A 65-year-old woman with persistent dyspnea, arthritis, and Raynaud's phenomenon","volume":"361","author":"Chong","year":"2021","journal-title":"Am J Med Sci"},{"issue":"4","key":"10.1016\/j.hrtlng.2024.07.010_bib0038","doi-asserted-by":"crossref","first-page":"693","DOI":"10.3899\/jrheum.100675","article-title":"An analysis of connective tissue disease-associated interstitial lung disease at a US Tertiary Care Center: better survival in patients with systemic sclerosis","volume":"38","author":"Su","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.hrtlng.2024.07.010_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2023.107242","article-title":"Comparison of the diagnostic criteria for progressive pulmonary fibrosis in connective tissue disease related interstitial lung disease","volume":"212","author":"Lee","year":"2023","journal-title":"Respir Med"},{"issue":"3","key":"10.1016\/j.hrtlng.2024.07.010_bib0040","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.03187-2021","article-title":"Progressive pulmonary fibrosis: an expert group consensus statement","volume":"61","author":"Rajan","year":"2023","journal-title":"Eur Respir J"}],"container-title":["Heart & Lung"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0147956324001377?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0147956324001377?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T22:19:54Z","timestamp":1728598794000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0147956324001377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":40,"alternative-id":["S0147956324001377"],"URL":"https:\/\/doi.org\/10.1016\/j.hrtlng.2024.07.010","relation":{},"ISSN":["0147-9563"],"issn-type":[{"value":"0147-9563","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A systematic review and meta-analysis of the clinical benefits and adverse reactions of anti-fibrotics in non-IPF progressive fibrosing ILD","name":"articletitle","label":"Article Title"},{"value":"Heart & Lung","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hrtlng.2024.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}